Dermata Therapeutics Reports Decreased Net Loss and Increased Assets in Latest 10-Q Filing

Dermata Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of $1.7 million for the three months ended June 30, 2025, a decrease from a net loss of $2.8 million during the same period in 2024. For the six months ending June 30, 2025, the net loss was $4.0 million, compared to $6.0 million for the first half of 2024. The reduction in losses is attributed to a decrease in operating expenses, which fell to $1.8 million in Q2 2025 from $2.9 million in Q2 2024, primarily due to lower research and development costs associated with the completion of the XYNGARI™ STAR-1 clinical trial.

The company’s total assets increased to $6.6 million as of June 30, 2025, up from $3.5 million at the end of 2024. This growth was driven by a significant rise in cash and cash equivalents, which reached $6.5 million, compared to $3.2 million at the end of the previous fiscal year. Dermata's total liabilities decreased to $1.0 million from $2.0 million, reflecting a reduction in accounts payable and accrued liabilities. The company’s stockholders’ equity also improved, rising to $5.6 million from $1.6 million, indicating a strengthening financial position.

Strategically, Dermata has made notable advancements, including the successful completion of the XYNGARI™ Phase 3 STAR-1 clinical trial, which met all co-primary endpoints. The trial demonstrated significant efficacy in reducing acne lesions, with a notable reduction in both inflammatory and non-inflammatory lesions. Following this success, the company is preparing for a second Phase 3 trial, STAR-2, as requested by the FDA. Additionally, Dermata has engaged in financing activities, raising approximately $7.9 million in the first half of 2025 through various equity offerings, including a private placement in January 2025 and a warrant inducement agreement in March 2025.

Operationally, Dermata has focused on enhancing its research and development capabilities, with a particular emphasis on its proprietary Spongilla technology platform. The company is also exploring collaborations to further its clinical trials and product development. As of June 30, 2025, Dermata had 637,757 shares of common stock outstanding, reflecting a reverse stock split executed in August 2025. The company anticipates continued net losses as it invests in the development of its product candidates, particularly XYNGARI™ and DMT410, and plans to seek additional capital to support its operations and growth initiatives.

Looking ahead, Dermata expects to continue incurring significant expenses related to clinical trials and regulatory approvals. The company has indicated that its existing cash resources are projected to fund operations into the second quarter of 2026, but it will need to raise additional capital to sustain its development efforts and achieve profitability. The management has outlined plans to mitigate financial risks, including potential equity or debt financing and strategic collaborations, to support its long-term growth objectives.